{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:15:37Z","timestamp":1780524937611,"version":"3.54.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Meshalkin National Medical Research Center"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The efficacy and safety of the Supera stent in superficial femoral artery (SFA) have been reported mostly in shorter lesions with relatively low proportion of occlusions. There are little data on the effectiveness of the Supera stent in long lesions. The aim of this study was to assess the clinical safety and efficiency of the Supera stent in the treatment of long femoropopliteal occlusive lesions (Trans-Atlantic Inter-Society Consensus [TASC] C\/D) in patients with symptomatic peripheral artery disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The STELLA-SUPERA-SIBERIA is a prospective, single-center, single-arm study. Patients with symptomatic (Rutherford stages 3\u20136) de novo and TASC C\/D occlusive lesions of the femoropopliteal segment were treated with Supera stent. The primary endpoint was the 12 month rate of primary sustained clinical improvement (upward shift on the Rutherford classification to a one level without the need for repeated target lesion revascularization (TLR) in surviving patients without the need for unplanned amputation). Secondary endpoints were the 24 month of primary sustained clinical improvement, MALE, limb salvage, the primary patency, the secondary patency, 24 month MACE. Follow-up included clinical examination, duplex scan, and biplane x-ray up to 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between April 2019 and January 2020, 52 symptomatic patients with 55 long femoropopliteal occlusive lesions (52.7% TASC D lesions and 47.3% TASC C lesions) were treated. The mean target lesion length was 205\u00b172 mm. All patients had total occlusions. The mean lesion length of the implanted Supera stents was 198\u00b182 mm. At 12 and 24 months, the primary sustained clinical improvement rate was 80.2% and 63.6%, respectively. The Rutherford category assessment was significantly improved at 24 months compared with baseline (p=0.02). The primary patency rate at 12 and 24 months was 78.1% and 60.0%, respectively. At 12 and 24 months, freedom from TLR was 83.5% and 81.8%, respectively. There were no stent fractures at 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Supera Stent implantation for TASC C\/D femoropopliteal lesions revascularization appears to be a safe and efficient implant given the complexity of the treated lesions. Head-to-head studies are mandatory to establish Supera Stent as an alternative tool to open surgery for long femoropopliteal lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>Our study indicated, that using self-expanding interwoven nitinol stent for TASC C\/D femoropopliteal lesions revascularization appears to be a safe and efficient implant given the complexity of the treated lesions. Although bypass grafting is recommended for prolonged femoropopliteal lesions, open surgery is more traumatic and is associated with greater risks than endovascular procedures. Our findings suggest that the use of interwoven nitinol stents can overcome the disadvantages of traditional stents in such cases, which may help to improve patients\u2019 outcomes and reduce the risk of adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028231170125","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T04:31:14Z","timestamp":1683001874000},"page":"192-198","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Long Femoropopliteal Occlusive Lesions With Self-expanding Interwoven Nitinol Stent: 24 Month Outcomes of the STELLA-SUPERA-SIBERIA Register Trial"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-7868","authenticated-orcid":false,"given":"Alexander A.","family":"Gostev","sequence":"first","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7418-3298","authenticated-orcid":false,"given":"Olesia O.","family":"Osipova","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-4607","authenticated-orcid":false,"given":"Alexey V.","family":"Cheban","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoraan B.","family":"Saaya","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem A.","family":"Rubtsun","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel V.","family":"Ignatenko","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Karpenko","sequence":"additional","affiliation":[{"name":"Center for Vascular and Hybrid Surgery, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gou\u00ebffic","sequence":"additional","affiliation":[{"name":"Laboratoire de Physiopathologie de la R\u00e9sorption Osseuse, Inserm-UN UMR-957, Nantes, France"},{"name":"Service de Chirurgie Vasculaire et Endovasculaire, Groupe Hospitalier Paris Saint Joseph, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"bibr1-15266028231170125","unstructured":"Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1):S1\u2013S109.e33. http:\/\/www.ejves.com\/article\/S1078588419303806\/fulltext. Accessed November 1, 2021."},{"key":"bibr2-15266028231170125","doi-asserted-by":"crossref","unstructured":"Lin Y, Tang X, Fu W, et al. Stent fractures after superficial femoral artery stenting: risk factors and impact on patency. J Endovasc Ther. 2015;22(3):319\u2013326. https:\/\/pubmed.ncbi.nlm.nih.gov\/25862365\/. Accessed May 4, 2022.","DOI":"10.1177\/1526602815580783"},{"key":"bibr3-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2018.0475"},{"key":"bibr4-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1177\/1526602816669135"},{"key":"bibr5-15266028231170125","doi-asserted-by":"crossref","unstructured":"Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13(6):701\u2013710. https:\/\/pubmed.ncbi.nlm.nih.gov\/17154704\/. Accessed September 5, 2022.","DOI":"10.1583\/05-1704.1"},{"key":"bibr6-15266028231170125","doi-asserted-by":"crossref","unstructured":"Garcia LA, Rosenfield KR, Metzger CD, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89(7):1259\u20131267. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28471091. Accessed September 2, 2019.","DOI":"10.1002\/ccd.27058"},{"key":"bibr7-15266028231170125","unstructured":"Bhatt H, Kovach R, Janzer S, et al. SUPERA stent outcomes in above-the-knee interventions: effects of COMPression and ELongation (SAKE-COMPEL) sub-study. Cardiovasc Revasc Med. 2018;19(5, pt A):512\u2013515. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29217340. Accessed September 2, 2091."},{"key":"bibr8-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1177\/1526602817753388"},{"issue":"6","key":"bibr9-15266028231170125","volume":"83","author":"Rocha Singh-KJ","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"bibr10-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(97)70045-4"},{"key":"bibr11-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2008.06.020"},{"key":"bibr12-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.000937"},{"key":"bibr13-15266028231170125","doi-asserted-by":"crossref","unstructured":"Montero-Baker M, Ziomek GJ, Leon L, et al. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent. J Vasc Surg. 2016;64(4):1002\u20131008. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27444365. Accessed September 2, 2019.","DOI":"10.1016\/j.jvs.2016.04.053"},{"key":"bibr14-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.09.018"},{"key":"bibr15-15266028231170125","doi-asserted-by":"crossref","unstructured":"Bosiers M, Torsello G, Gi\u00dfler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16(3):261\u2013269. https:\/\/journals.sagepub.com\/doi\/abs\/10.1583\/08-2676.1. Accessed October 27, 2021.","DOI":"10.1583\/08-2676.1"},{"key":"bibr16-15266028231170125","doi-asserted-by":"crossref","unstructured":"Nasr B, Gouailler F, Marret O, et al. Treatment of long femoropopliteal lesions with self-expanding interwoven nitinol stent: 24 month outcomes of the STELLA-SUPERA trial. J Endovasc Ther. 2023;30:98\u2013105. https:\/\/pubmed.ncbi.nlm.nih.gov\/35114841\/. Accessed October 24, 2022.","DOI":"10.1177\/15266028221075227"},{"key":"bibr17-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.01.080"},{"key":"bibr18-15266028231170125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.11.015"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028231170125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028231170125","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028231170125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:31:24Z","timestamp":1777498284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028231170125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/15266028231170125"],"URL":"https:\/\/doi.org\/10.1177\/15266028231170125","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}